Results 71 to 80 of about 589,865 (354)

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Evaluation of clinical features, treatment approaches and treatment outcomes of children with non-Hodgkin lymphoma

Journal of Contemporary Medicine, 2022
Aim: To evaluate the demographic and clinical characteristics, treatment approaches and outcomes of our pediatric patients with non-Hodgkin lymphoma diagnosed and treated in our center. Material and Methods: Between 2006 and 2002, the oncologic charts of
Kübra Ertan, Serdar Uğraş, Yavuz Köksal, Buket Kara   +3 more
doaj   +1 more source

Safety and preliminary efficacy of vorinostat with R-EPOCH in high-risk HIV-associated non-Hodgkin\u27s lymphoma (AMC-075) [PDF]

, 2018
We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma.
Aboulafia, David, Ambinder, Richard F, Cesarman, Ethel, Henry, David, Lee, Jeanette Y, Mitsuyasu, Ronald, Moore, Page C, Noy, Ariela, Ramos, Juan C, Ratner, Lee, Reid, Erin G, Rudek, Michelle A, Sparano, Joseph A   +12 more
core   +2 more sources

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy, 2023
Tesfaye Gessese,1 Fikir Asrie,2 Zewudu Mulatie1 1Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia; 2Department of Hematology and Immunohematology, School of Biomedical and Laboratory ...
Gessese T, Asrie F, Mulatie Z
doaj  

Low-dose CT radiomics features-based neural networks predict lymphoma types

The Egyptian Journal of Radiology and Nuclear Medicine, 2023
Background Fluorodeoxyglucose positron emission tomography (PET)–computed tomography (CT) is preferred for pretreatment staging and treatment planning in patients with lymphoma.
Hasan Erturk, Mehmet Bilgin Eser, Aysenur Buz Yaşar, Muzaffer Ayaz, Basak Atalay, Mehmet Tarık Tatoglu, Ismail Caymaz   +6 more
doaj   +1 more source

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells [PDF]

, 2023
Fabio Guolo, Paola Minetto, Silvia Pesce, Filippo Ballerini, Marco Greppi, Matteo Bozzo, Michele Cea, Maurizio Miglino, Andrea Todiere, Elisabetta Tedone, Nicoletta Colombo, Alessandra Bò, Alberto Serio, Silvia Luchetti, Alida Dominietto, Riccardo Varaldo, Simona Candiani, Marco Mora, Paolo Nozza, Genny Del Zotto, Emanuela Marcenaro, Roberto M. Lemoli   +21 more
openalex   +1 more source

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies

OncoTarget, 2017
Immune checkpoint blockade therapeutics, notably antibodies targeting the programmed death 1 (PD-1) receptor and its PD-L1 and PD-L2 ligands, are currently revolutionizing the treatment of cancer.
P. Gravelle, B. Burroni, S. Péricart, C. Rossi, C. Bezombes, M. Tosolini, D. Damotte, P. Brousset, J. Fournié, C. Laurent   +9 more
semanticscholar   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

Role of non‐chromosomal birth defects on the risk of developing childhood Hodgkin lymphoma: A Children's Oncology Group study [PDF]

, 2023
Erin C. Peckham‐Gregory, Lucas Maschietto Boff, Jeremy M. Schraw, Logan G. Spector, Amy M. Linabery, Erik B. Erhardt, Karina Braga Ribeiro, Carl E. Allen, Michael E. Scheurer, Philip J. Lupo   +9 more
openalex   +1 more source